Journal Article

Access to innovative therapies in pediatric oncology: Report of the nationwide experience in Canada

Judd, Sandra, Whitlock, James A., Revon‐Riviere, Gabriel, Brossard, Josee, Deyell, Rebecca J., Pecheux, Lucie, Vanan, Magimairajan Issai, Lewis, Victor A., Santiago, Raoul, Grover, Stephanie A., Cohen‐Gogo, Sarah, Morgenstern, Daniel A., Moorehead, Paul, Portwine, Carol, Denburg, Avram, Goudie, Catherine, Tran, Thai Hoa, Abbott, Lesleigh S., Alvi, Saima, Zorzi, Alexandra P.

2024

Overview

Background The need for new therapies to improve survival and outcomes in pediatric oncology along with the lack of approval and accessible clinical trials has led to “out‐of‐trial” use of innovative therapies. We conducted a retrospective analysis of requests for innovative anticancer therapy in Canadian pediatric oncology tertiary centers for patients less than 30 years old between 2013 and 2020. Methods Innovative therapies were defined as cancer‐directed drugs used (a) off‐label, (b) unlicensed drugs being used outside the context of a clinical trial, or (c) approved drugs with limited evidence in pediatrics. We excluded cytotoxic chemotherapy, cellular products, and cytokines. Results We retrieved data on 352 innovative therapy drug requests. Underlying diagnosis was primary CNS tumor 31%; extracranial solid tumor 37%, leukemia/lymphoma 22%, LCH 2%, and plexiform neurofibroma 6%. RAS/MAP kinase pathway inhibitors were the most frequently requested innovative therapies in 28% of all requests followed by multi‐targeted tyrosine kinase inhibitors (17%), inhibitors of the PIK3CA‐mTOR‐AKT pathway (8%), immune checkpoints inhibitors (8%), and antibody drug conjugates (8%). In 112 out of 352 requests, innovative therapies were used in combination with another anticancer agent. 48% of requests were motivated by the presence of an actionable molecular target. Compassionate access accounted for 52% of all requests while public insurance was used in 27%. Mechanisms of funding varied between provinces. Conclusion This real‐world data collection illustrates an increasing use of “out‐of‐trial” innovative therapies in pediatric oncology. This new field of practice warrants further studies to understand the impact on patient trajectory and equity in access to innovative therapies.

• Publisher: John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
• Subject: Adult / AKT protein / Antineoplastic Agents - therapeutic use / Antineoplastic drugs / Bone cancer / Canada / Cancer therapies / Chemotherapy / Child / Clinical trials / Cytokines / Cytotoxicity / Data collection / Drugs / Enzyme inhibitors / Funding / Humans / Immune checkpoint / Immunosuppressive agents / immunotherapy / Kinases / Leukemia / Lymphoma / MAP kinase / Medical Oncology / Mutation / Neoplasms - drug therapy / Oncology / Patients / Pediatrics / Pharmaceutical industry / Plexiform neurofibroma / Precision medicine / precision oncology / real‐world data / Reimbursement / Research ethics / Retrospective Studies / Sarcoma / Solid tumors / targeted therapy / Therapies, Investigational / TOR protein